(Q33183187)

23 July 2017

title

The use of oral cytotoxic and cytostatic drugs in cancer treatment (English)

1 reference

23 July 2017

Sparreboom A

1

1 reference

23 July 2017

de Jonge MJ

series ordinal

2

1 reference

23 July 2017

Verweij J

series ordinal

3

1 reference

23 July 2017

publication date

1 January 2002

1 reference

European Journal of Cancer

23 July 2017

published in

1 reference

23 July 2017

volume

38

1 reference

23 July 2017

issue

1

1 reference

23 July 2017

page(s)

18-22

1 reference

Patient preferences for oral versus intravenous palliative chemotherapy

23 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900322-7

7 January 2021

Oral topoisomerase 1 inhibitors in adult patients: present and future

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900322-7

7 January 2021

A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900322-7

7 January 2021

Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900322-7

7 January 2021

Oral topotecan: bioavailablity and effect of food co-administration

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900322-7

7 January 2021

Population pharmacokinetic model for topotecan derived from phase I clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900322-7

7 January 2021

Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900322-7

7 January 2021

Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900322-7

7 January 2021

Oral chemotherapy: rationale and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900322-7

7 January 2021

Modulation of oral bioavailability of anticancer drugs: from mouse to man.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900322-7

7 January 2021

Active secretion and enterocytic drug metabolism barriers to drug absorption

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900322-7

7 January 2021

Does P-glycoprotein play a role in anticancer drug pharmacokinetics?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900322-7

7 January 2021

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900322-7

7 January 2021

Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900322-7

7 January 2021

Oral delivery of taxanes

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900322-7

7 January 2021

Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900322-7

7 January 2021

Tacrolimus oral bioavailability doubles with coadministration of ketoconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900322-7

7 January 2021

Pharmacology of fluorinated pyrimidines: eniluracil

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900322-7

7 January 2021

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900322-7

7 January 2021

Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900322-7

7 January 2021

St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900322-7

7 January 2021

Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900322-7

7 January 2021

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900322-7

7 January 2021

10.1016/S0959-8049(01)00322-7

Identifiers

DOI

1 reference

23 July 2017

1 reference